Preliminary Insights in Oxytocin Association with the Onset of Diabetic Neuropathy

Kobylinska, Liana; Ma, Ghita; Căruntu, Constantin; Gabreanu, G; Cp, Tataru; Sv, Bădescu; Geicu, Ovidiu Ionuț; Neagu, Monica; Constantin, Carolina; Dobrescu, Iuliana; Zăgrean, Leon

doi:10.4183/aeb.2017.249

Cited by 5 publications

(4 citation statements)

References 36 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the quality of samples and to the processing, some neuropeptides were not measured for all the patients. For each neuropeptide mentioned, the non-accurate measurements were excluded from the report (31).…”

Section: Sample Processing and Neuropeptides' Level Measurementsmentioning

confidence: 99%

Plasmatic Levels of Neuropeptides, Including Oxytocin, in Children with Autism Spectrum Disorder, Correlate with the Disorder Severity

et al. 2019

Self Cite

View full text Add to dashboard Cite

Context. Oxytocin has been investigated as a potential medication for psychiatric disorders. Objective and design. This study prospectively investigates correlations between oxytocin and other neuropeptides plasma levels in patients with autism spectrum disorders (ASD) according to severity and treatment, as compared to controls. Subjects and methods. Thirty-one children (6 neurotypical as control) participated in this study. The patients were classified into mildly and severely-affected, according to Autism Diagnostic Observation Schedule (ADOS) scores. Oxytocin, orexin A and B, α-MSH, β-endorphins, neurotensin and substance P were investigated using a quantitative multiplex assay or a competitive-ELISA method. Results. Plasma oxytocin levels differed between the groups (F (2, 24) =6.48, p=0.006, η2=0.35, observed power=86%): patients with the mild ASD had higher values of plasma oxytocin than those with the severe form (average difference=74.56±20.74pg/mL, p=0.004). Conclusions. These results show a negative correlation between plasma levels of oxytocin and the severity of ASD and support the involvement of oxytocinergic mechanisms in ASD.

show abstract

Section: Sample Processing and Neuropeptides' Level Measurementsmentioning

confidence: 99%

Plasmatic Levels of Neuropeptides, Including Oxytocin, in Children with Autism Spectrum Disorder, Correlate with the Disorder Severity

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Oxytocin is a neurohormone, synthetized primarily by the hypothalamus, but also in other brain areas, such as the pineal gland (5), that mediates numerous physiological effects including milk ejection, parturition and maternal-foetal interactions. Recent studies have also investigated oxytocin's direct effects on the brain during different physiological and pathological conditions (6)(7)(8)(9)(10). In the immature brain, oxytocin has been found to modulate brain's excitability by promoting near-term excitatory-to-inhibitory switch in GABA action (11) and has been found to exert a prolonged neuroprotective action on hippocampal neurons subjected to an in vitro model of transient hypoxia-ischemia (12).…”

Section: Introductionmentioning

confidence: 99%

Oxytocin Reduces Seizure Burden and Hippocampal Injury in a Rat Model of Perinatal Asphyxia

et al. 2018

View full text Add to dashboard Cite

Context. Foetal asphyxia, a frequent birth complication, detrimentally impacts the immature brain, resulting in neuronal damage, uncontrolled seizure activity and long-term neurological deficits. Oxytocin, a neurohormone mediating important materno-foetal interactions and parturition, has been previously suggested to modulate the immature brain's excitability, playing a neuroprotective role. Our aim was to investigate the effects of exogenous oxytocin administration on seizure burden and acute brain injury in a perinatal model of asphyxia in rats. Animals and methods. Asphyxia was modelled by exposing immature rats to a 90-minute episode of low oxygen (9% O 2) and high CO 2 (20% CO 2). Control rats were kept in ambient room-air for the same time interval. In a third group of experiments, oxytocin (0.02 UI/g body weight) was nasally administered 30 minutes before the asphyxia episode. Seizure burden was assessed by the cumulative number of loss of righting reflex (LRR) over a two-hour postexposure period. Acute brain injury was assessed through hippocampal S-100 beta, a biomarker of cellular injury, 24-hours after exposure. Results. Asphyxia increased both LRR and hippocampal S-100 beta protein compared to controls, and these effects were significantly reduced by oxytocin administration. Conclusion. Oxytocin treatment decreased both seizure burden and hippocampal injury, supporting a potential neuroprotective role for oxytocin in perinatal asphyxia.

show abstract

“…Before surgery, patients with diabetes mellitus. Without apparent ocular complications, were referred to a diabetes centre in order to evaluate the risk of optic neuropathy [32] and other ocular complications. All surgeries were performed using the 193 nm wavelength excimer laser system Wavelight EX500 (Alcon Laboratories, Inc., Fort Worth, TX) by the same surgeon and aimed for emmetropia as a refractive target.…”

Section: Procedures Methodologymentioning

confidence: 99%

EFFECT OF MITOMYCIN C 0.02% ON ENDOTHELIAL CELLS DURING STREAMLIGHT TransPRK FOR PATIENTS WITH LOW- MODERATE MYOPIA/ASTIGMATISM

SIMA

2023

FARMACIA

View full text Add to dashboard Cite

Mitomycin C is an antimetabolite with an important anti-mitotic effect on cellular proliferation, also used as adjunctive therapy for haze prophylaxis after corneal surface ablation techniques. In this study, 60 eyes undergoing refractive surgery (Streamlight TransPRK) were allocated randomly into two groups of 30 eyes each: Group I: without the use of Mitomycin C 0.02% (MMC) and Group II: with intraoperative MMC 0.02% use for 20 seconds. Refractive results, efficacy, safety and endothelial layer function and morphology were evaluated during the three-month follow-up. The main outcome measures were endothelial cell density (ECD), coefficient of variation (CV), central corneal thickness (CCT), hexagonal cell percentage (HEX), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA) and mean refractive spherical equivalent (MRSE). The assessments were compared between groups. After three months, the mean ECD decreased in both groups, the morphology and distribution of endothelial cells suffered modifications in both groups, with statistically insignificant differences between groups. In conclusion, intraoperative topical application of 0.1 mL of a 0.02% solution of mitomycin C on patients with low to moderate myopia with or without astigmatism undergoing Streamlight TransPRK does not have a negative impact on endothelial cell layer function or morphology. RezumatMitomicina C este un antimetabolit cu un important efect antimitotic asupra proliferării celulare, utilizat și ca terapie adjuvantă în prevenția haze-ului cornean rezultat în urma tehnicilor de ablație cu laserul a suprafeței corneene. În acest studiu, 60 de ochi ce au beneficiat de chirurgie refractivă (Streamlight TransPRK) au fost distribuiți aleatoriu în două grupuri de câte 30 de ochi fiecare: grupul I, fără utilizarea Mitomicinei C 0.02%, şi grupul II, în care s-a utilizat intraoperator MMC 0.02% timp de 20 de secunde. Au fost evaluate timp de trei luni rezultatele refractive, eficiența, siguranța, morfologia și funcția stratului celulelor endoteliale corneene. Principalele măsurători au cuprins: densitatea celulelor endoteliale (ECD), coeficientul de variație (CV), grosimea centrală corneană (CCT), procentajul celulelor hexagonale (HEX), acuitățile vizuale necorectate și optim corectate, precum și echivalentul sferic refractiv. Rezultatele au fost comparate între grupuri. După trei luni densitatea celulelor endoteliale, morfologia și distribuția acestora s-au modificat în ambele grupuri fără diferențe semnificativ statistice între ele. În concluzie, aplicarea intraoperatorie a 0.1 mL de soluție de mitomicină C 0.02% timp de 20 de secunde la pacienții cu miopie ușoară-moderata cu sau fără astigmatism ce beneficiază de Streamlight TransPRK, nu a avut un impact negativ asupra funcției sau morfologiei stratului celulelor endoteliale.

show abstract

Preliminary Insights in Oxytocin Association with the Onset of Diabetic Neuropathy

Cited by 5 publications

References 36 publications

Plasmatic Levels of Neuropeptides, Including Oxytocin, in Children with Autism Spectrum Disorder, Correlate with the Disorder Severity

Plasmatic Levels of Neuropeptides, Including Oxytocin, in Children with Autism Spectrum Disorder, Correlate with the Disorder Severity

Oxytocin Reduces Seizure Burden and Hippocampal Injury in a Rat Model of Perinatal Asphyxia

EFFECT OF MITOMYCIN C 0.02% ON ENDOTHELIAL CELLS DURING STREAMLIGHT TransPRK FOR PATIENTS WITH LOW- MODERATE MYOPIA/ASTIGMATISM

Contact Info

Product

Resources

About